anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a medical-magnetic-thermal compounding body-building magnetic clasp for human acupunctures, and a manufacturing method and a using method of the medical-magnetic-thermal compounding body-building magnetic clasp. The body-building magnetic clasp comprises a piston tube; one section of the piston tube is a compound body-building drug filling section which is filled with magnetic powder/ iron powder, compatible traditional Chinese medicines and electrical mountain flour; the other section of the piston tube is a piston movement section; a piston sealing disc is arranged in the piston movement section; a piston rod used for pushing and pulling the piston sealing disc is arranged on the piston sealing disc; and the body-building magnetic clasp can be used for medical therapy, magnetic therapy and thermal therapy of a human body. The manufacturing method comprises the following steps: manufacturing the piston tube; arranging the piston sealing disc and the piston rod in the piston movement section; and filling the compound body-building drug filling section with compound body-building drugs. The body-building magnetic clasp is simple in manufacturing process, and lower in cost. The using method comprises the following steps: using an A-type body-building magnetic clasp and a B-type body-building magnetic clasp synchronously to form magnetic fields, filling the A-type body-building magnetic clasp with magnetic powder, and filling the B-type body-building magnetic clasp with iron powder. The body-building magnetic clasp has a remarkable effect on promotion of human meridian activity and realizes a magnetic therapy body-building effect on the human body.
Sepsis is currently defined as life-threatening organ dysfunction secondary to a dysregulated host response to infection (Sepsis-3). Septic shock is a subgroup of patients who also have sustained arterial hypotension requiring vasopressors and tissue dysoxia. The mortality varies from 10 to 40% depending on the severity. The latest "bundles" of the SSC request to perform within the first hour of sepsis identification a fluid loading of 30 mL/kg of crystalloids in the presence of hypotension, and to initiate a vasopressor support in case of persistent hypotension to maintain a mean arterial pressure ≥ 65 mmHg. However, early fluid resuscitation is not necessarily associated with an improvement of sepsis prognosis and may even be deleterious when leading to excessive positive fluid balance. Accordingly, the SSC recommends investigating a personalized approach to define for each patient the appropriate volume of fluids to be administered according to the initial mechanism of sepsis-induced cardiovascular failure. Echocardiography is currently recommended as a first-line modality to identify the origin of acute circulatory failure, sepsis remaining the leading cause. It has been shown to alter ongoing treatment based on the sole SSC recommendations in the intensive care unit. In contrast, the impact of hemodynamic assessment using echocardiography at the early stage of sepsis in patients admitted to the Emergency Department (ED) is unknown.

In this randomized trial, patients will be either assessed hemodynamically using transthoracic echocardiography to guide early therapeutic management (intervention arm) or managed according to standards of care based on current SSC recommendations (control arm). Early echocardiography will be performed after 500 mL of fluid loading initiated upon identification of septic patients based on the qSOFA score (hemodynamic criterion required: systolic blood pressure ≤ 100 mmHg). This will allow identifying the hemodynamic profile at the origin of sepsis-induced circulatory failure and to monitor both the efficacy and tolerance of fluid resuscitation, or of any other therapeutic intervention (e.g., inotropic support) according to a predefined therapeutic algorithm. Patients allocated to the control arm will be managed conventionally according to current SSC recommendations, including a standardized fluid loading of 30 mL/kg.

Organ dysfunctions will be assessed in the two study arms by the SOFA score 24 hours after randomization and patient will be followed up until hospital discharge to determine outcome.
The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the "Nutritional Knowledge Level Scale for Adults" were filled with the volunteer ones face-to-face at their homes, complying with the social distance rules before the training. After the data was collected, the women in the intervention group were trained on "Hand-Washing and Nutrition during the COVID-19 period". The training on hand-washing and nutrition was given using the "Hand-Washing and Nutrition Training Guide" prepared by the researchers, and the "Hand-Washing and Nutrition Training Manual" covering the content of the training, was distributed to the women at the end of the training. The data collection forms were re-filled three months after the training.
Isoniazid is an antibacterial available as 100 mg and 300 mg tablets for oral administration. Each tablet also contains as inactive ingredients: anhydrous lactose, calcium stearate, colloidal silicon dioxide, microcrystalline cellulose, and stearic acid.

Isoniazid is chemically known as isonicotinyl hydrazine or isonicotinic acid hydrazide. It has an empirical formula of C6H7N3O and a molecular weight of 137.14. It has the following structure:

Isoniazid is odorless, and occurs as a colorless or white crystalline powder or as white crystals. It is freely soluble in water, sparingly soluble in alcohol, and slightly soluble in chloroform and in ether. Isoniazid is slowly affected by exposure to air and light.
Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. The results of multiplex PCR will be not informed to the medical researcher, being focused care as a result of blood culture (at least after 72 hours).
This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. 
     The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.
During parturition, cows often experience intense pain and stress, which increases the risk of inflammatory diseases. This study aimed to compare the postpartum health status between healthy cows and those diagnoses with inflammatory diseases by examining behavioral and heart rate (HR) variability (HRV) changes, to provide information before the onset of disease. Eight Holstein cows were used in this study. HR, parameters of HRV (low-frequency power: LF; high-frequency power: HF; LF/HF ratio, and total power) and time budget of individual maintenance behaviors (standing, recumbency, feeding, rumination while standing and lying, and sleep) were continuously recorded from 0 to 168 h postpartum. Milk and blood samples were collected daily. Cows were categorized as diseases based on the positive result of California mastitis test and/or serum haptoglobin concentration that exceeded 50 μg/ml after all blood samples have been collected. Compared to healthy individuals (n = 3), diseased cows (n = 5) exhibited higher HR, LF/HF, and lower total power (p < 0.05), suggesting the dominance of the sympathetic nervous system in cows with inflammatory diseases. Additionally, diseased cows showed an increased standing time budget and reduced recumbency (p < 0.05), which may be a behavioral strategy in response to discomfort from inflammation.
The invention provides a prodrug compound which can be activated by active oxygen species and aims at releasing indometacin, and a preparation method and application thereof. The compound has a structure shown in formula I. The prodrug can be activated by active oxygen to release the drug indomethacin. The invention also provides a method for preparing the compound. The compound can be used for preparing medicaments for treating diseases related to oxidative stress, and can also be used for beautifying and health care. The compound provided by the invention has good response performance to active oxygen, has a relatively quick response time, can work in a relatively large pH range, and has a relatively wide application range.
The present invention relates to the discovery that Tat polypeptides may be used as immunoregulators to enhance the immune response to infectious diseases. More particularly, Tat polypeptides may be used as immunoregulators to enhance immune responses to microbial infections, for example, viral and bacterial infections. In accordance with the present invention, Tat polypeptides interact with CCR3 to stimulate platelet activation. The novel finding of the present inventors, therefore, presents new applications for which Tat nucleic and amino acid sequences, and compositions thereof may be used to advantage. Applications for which the Tat nucleic and amino acid sequences and compositions thereof of the invention may be used include, but are not limited to, various research and therapeutic applications as described herein. Also provided is a kit comprising Tat nucleic and/or amino acid sequences, Tat activity compatible buffers, and instruction materials.
The invention discloses a drug for treating multiple epiphyseal dysplasia. The drug is applied to the treatment of multiple epiphyseal dysplasia. The drug is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: litchi chinensis Sonn., bombax malabaricum peel, poriacocos (Schw.) Wolf, citrus reticulata Blanco, aeschynomene indica L., trachelospermum jasminoides (Lindl.) Lem., radix puerariae, paris polyphylla Sm., luffa cylindrica (L.) Roem., murraya jasminorage, hordeum vulgare L. and setaria italica (L.) Beauv.. Proved by clinical trials, the drug has the characteristics of good treatment effect and high safety in the treatment of multiple epiphyseal dysplasia, so that the method is worthy of clinical application and popularization.
SSRIs, including CELEXA, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7)]. Serotonin syndrome can also occur when these drugs are used alone. Symptoms of serotonin syndrome were noted in 0.1% of MDD patients treated with CELEXA in premarketing clinical trials.

Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). 

The concomitant use of CELEXA with MAOIs is contraindicated. In addition, do not initiate CELEXA in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking CELEXA, discontinue CELEXA before initiating treatment with the MAOI [see Contraindications (4), Drug Interactions (7)].

Monitor all patients taking CELEXA for the emergence of serotonin syndrome. Discontinue treatment with CELEXA and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of CELEXA with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
PURPOSE: An extract of Acer mono Max. leaf and phenolic compounds isolated therefrom are provided, which Acer mono Max. leaf extract and phenolic compounds isolated therefrom have improved hepatoprotective activity, so that they are useful for prevention and treatment of liver disease. CONSTITUTION: The composition for prevention and treatment of liver disease comprises the C1-4 alcohol extract of Acer mono Max. leaf, wherein the composition comprises n-hexane fraction, CHCl3 fraction, EtOAc fraction, n-BuOH fraction and water fraction of the alcohol extract of Acer mono Max. leaf. The composition for prevention and treatment of liver disease comprises a compound of formula (1) as an effective component, wherein R1 is hydrogen or optionally substituted aryl; R2 is hydrogen or OR11; R11 is hydrogen or rhamnose; and R3 is hydrogen or glucose. The composition for prevention and treatment of liver disease comprises a compound of formula (2) as an effective component, wherein R4 is hydrogen or apiose; and R5 and R6 are independently hydrogen or hydroxyl.
A method of interfering with the interaction and/or function of α1-antichymotrypsin (ACT) and Alzheimer's β-protein and, as a result, reducing the adverse side effects associated with formation of a complex comprising the two or with activity of the complex components. In one embodiment, the subject invention relates to methods of interfering with formation of a specific complex between ACT and β-protein. In another embodiment, the present invention relates to methods of inhibiting the function of the components of the ACT-β-protein complex. In particular, it relates to methods of inhibiting the function of β-protein, particularly enzymatic activity, such as esterase (cholinesterase) or protease activity. Both methods are useful in treating or preventing the effects of complex formation or of the enzymatic activity of the β-protein and, thus, provide a potential method of treating or preventing Alzheimer's disease, Down's syndrome or normal aging. Compositions and compounds useful in the method are also the subject of this invention.
BACKGROUND: In 2020, almost 100 million people were blind or visually impaired from cataract. Cataract surgery is a cost-effective treatment for cataracts. In Nigeria, twice as many women are cataract blind as men. Cataract surgical rate (CSR, the number of cataract operations per million population per year in a defined geographical location) is an output indicator of cataract surgical services. The recommended target CSR for sub-Saharan Africa is 1000/year. The aim of this study was to assess the CSR in men and women in Imo state, Nigeria.
METHODS: A retrospective review of cataract surgery undertaken in all eye health facilities in Imo State in 2019. Data collected included the type and location of facilities, patient demographics and the number and type of cataract operations performed in each facility. The CSR was calculated overall, in men and women, and in younger and older women.
RESULTS: The CSR overall was 330/million and was slightly higher in women (347/million) than in men (315/million) (p<0.001). More elderly women (≥65 years) accessed cataract surgery through outreach than men and younger women (OR 1.5 (95% CI 1.03 to 2.22, p=0.03) and 1.6 (95% CI 1.07 to 2.44, p=0.02)), respectively.
CONCLUSION: The overall CSR in Imo state was approximately one-third of that recommended for sub-Saharan Africa. Although the CSR was higher in women than in men, considerably higher CSRs are needed in women to address their higher burden of cataract blindness. Operational and intervention science research are needed, to identify and evaluate interventions which address demand and supply barriers to accessing cataract surgery, particularly for elderly women.
OBJECTIVES: I. Evaluate the safety of sequentially administered vaccinia-carcinoembryonic antigen (CEA) vaccine and ALVAC-CEA vaccine (CEA-Avipox vaccine) in two schedules and with the addition of sargramostim (GM-CSF) plus or minus interleukin-2 (IL-2) in patients with CEA expressing tumors. II. Compare the CEA-specific cellular immune response in cancer patients randomized to receive a single vaccination with vaccinia-CEA vaccine followed by three boosts with ALVAC-CEA vaccine (V-A-A-A) or the reverse vaccination sequence (A-A-A-V). III. Determine whether the addition of GM-CSF alone or with IL-2 enhances the immune response to sequentially administered vaccinia-CEA vaccine and ALVAC-CEA vaccine. IV. Compare the enzyme linked immunosorbent assay ELISPOT with lymphoproliferative and cytotoxicity assays for measuring CEA-specific T lymphocyte immune response.

OUTLINE: This is two-stage, partially randomized study. In stage one, patients are randomized to arm I or II. Arm I: Patients receive vaccinia-carcinoembryonic antigen (CEA) vaccine intradermally on day 1 of course 1 and ALVAC-CEA vaccine (CEA-Avipox vaccine) intramuscularly (IM) on day 1 of courses 2-4. Each course lasts 28 days. Arm II: Patients receive ALVAC-CEA vaccine (CEA-Avipox vaccine) IM on day 1 of courses 1-3 and vaccinia-CEA vaccine intradermally on day 1 of course 4. Each course lasts 28 days. Patients in arms I and II continue 28-day courses through month 6 and then receive 3-month courses for 2 years in the absence of disease progression or unacceptable toxicity. In stage two, patients are enrolled successively into arms III and IV. Arm III: Patients receive vaccines according to whichever schedule (arm I or II) was found to be superior plus sargramostim (GM-CSF) subcutaneously (SC) on days 1-4 of each course. Each course lasts 28 days. Arm IV: Patients receive vaccines plus GM-CSF as in arm III and interleukin-2 SC once daily on days 7-11 of each course. Each course lasts 28 days. Patients on arms III and IV continue 28-day courses through month 6 and then receive 3-month courses for 2 years in the absence of disease progression or unacceptable toxicity. If 2 or more patients in either arm III or IV experience dose limiting toxicity, accrual into study stops. Otherwise, the best response among the 4 arms is determined and further HLA-A2 positive patients are enrolled into that arm so that a total of 6 HLA-A2 positive patients with advanced disease and 6 HLA-A2 positive patients with NED (without radiographic or clinical evidence of tumor) are treated. If more than one regimen is equally superior, the least toxic regimen is chosen for further accrual. Patients are followed at 28 days following the last vaccination.

PROJECTED ACCRUAL: A minimum of 24 patients (6 HLA-A2 positive and up to 3 HLA-A2 negative patients per arm) will be accrued for this study.
PURPOSE:A dentifrice composition, containing a specific flavonoid compound as an active constituent, capable of exhibiting improved deodorant effect and convertible into a dosage form, e.g. toothpaste, tooth powder or mouthwash, etc., useful as a foul breath inhibitor. CONSTITUTION:A dentifrice composition containing one or two or more flavonoid compounds selected from flavonol, chrysin, hesperetin and hesperidin as an active constituent in an amount of 0.001-0.1wt%. The above-mentioned composition may be obtained by incorporating the active constituent with a base e.g. surfactant, polishing agent, binder sweetener, etc., and another drug active agent normally incorporated in dentifrice agents may be incorporated in the above-mentioned compositon. A preservative, colorant, perfume, etc., may be further incorporated therein.
All subjects that had access to the "nasopharyngeal swabs" service of the hospital for the detection of the Sars-CoV-2 virus, both hospitalized and discharged from the hospital and not hospitalized, from mid-May to the end of June 2020, will be consecutively enrolled. It is assumed that 500 people will be recruited.
In this study, the impact of chitosan (CS) and maitake (GF) nanoparticles towards the renal toxicity induced by Ehrlich ascites carcinoma (EAC) in vivo model was conducted. Besides benchmark negative control group, EAC model was constructed by intraperitoneal injection (i.p.) of 2.5 × 106 cells. Alongside positive control, two groups of EAC-bearing mice received 100 mg/kg of CS and GF nanoparticles/body weight daily for 14 days. The kidney function was conducted by measuring urea, creatinine, ions, (anti)/oxidative parameters and DNA damage. Also, measuring immunoreactivity of P53, proliferating cell nuclear antigen (PCNA), and B-cell lymphoma 2 (Bcl-2) and apoptosis protein. The outcomes illustrated notable kidney toxicity, which indicated by elevations in urea, creatinine, oxidative stress, DNA damage and induction of apoptosis. These events were supported by the drastic alteration in kidney structure through histological examination. Administration of CS and GF nanoparticles was able to enhance the antioxidant power, which further reduced oxidative damage, DNA injury, and apoptosis. These results indicated the protective and therapeutic role of biogenic chitosan and maitake nanoparticles against nephrotoxicity.
PROBLEM TO BE SOLVED: To provide an artificial tooth that presents an opal effect further approximated to a natural tooth in the cutting edge, etc.SOLUTION: An artificial tooth 1 has an enamel layer where a labial enamel layer 4a and a lingual enamel layer 4b are joined in the cutting edge. The labial enamel layer and the lingual enamel layer are formed by polymerization and curing of a resin matrix monomer of a composition containing 20-180 pts.wt. of an organic filler and 0.01-20 pts.wt. of an inorganic filler having an average particle size of 0.11-0.25 μm to 100 pts.wt. of the resin matrix monomer. The labial enamel layer and the lingual enamel layer are formed by a composition different in the composition, and a color tone expressed by an opal effect in the transmitted light is different.
Erythromycin is produced by a strain of Streptomyces erythraeus and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. 

Erythromycin lactobionate for injection, USP is a soluble salt of erythromycin suitable for intravenous administration. It is available as a sterile, lyophilized powder in vials containing the equivalent of 500 mg of erythromycin activity. It is prepared as a solution and lyophilized in its final container. 

Erythromycin lactobionate is chemically known as erythromycin mono (4-0-β-D-glactopyranosyl-D-gluconate) (salt). The structural formula is:
Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point.